Premium
31 P MRS as an early prognostic indicator of patient response to chemotherapy
Author(s) -
Redmond O. M.,
Stack J. P.,
O'Connor N. G.,
Carney D. N.,
Dervan P. A.,
Hurson B. J.,
Ennis J. T.
Publication year - 1992
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.1910250104
Subject(s) - chemotherapy , medicine , oncology
In this study 31 P spectral changes were closely monitored following the initial administration of cytotoxic drugs and related to five parameters of patient response. Pre‐ and postchemotherapy 31 P MRS examinations were performed on 16 patients with large, malignant tumors. These included four tumor types: (i) lymphoma (n = 7),(ii) breast carcinoma ( n = 4), (iii) musculoskeletal tumors ( n = 4), and (iv) adenocarcinoma ( n = 1). A mean of 5 spectra/patient (range 2–10) was performed following the initial chemotherapy. The spectral trends exhibited by 14 of 16 patients reached “points of maximum change,” after which they began to revert toward prechemotherapy values. In 2 of 16 patients that did not respond to the initial chemotherapy regimen, no spectral trends were observed. The degree of change of certain spectral parameters, namely, decreases in PME, PME/ PDE, PME/PCr, PME/NTP, PDE/PCr, and tumor pH, as well as increases in the ratios P i /PME and P i /PDE, were associated with good patient response and separated responders from nonresponders. Pi/PME appears the most promising for discriminating partial from Complete responders.